Drug firm Zydus Cadila on Thursday said it has applied for emergency use authorisation (EUA) with the Indian drug regulator for its three-dose COVID-19 vaccine ZyCoV-D, and plans to manufacture......
So far, no other vaccine has been approved globally for children below 12 years.Sohini Das reports. IMAGE: A beneficiary receives a dose of the Covid-19 vaccine at a vaccination centre in......
This could also be India's first vaccine for children aged 12 years and above as the company has conducted trials on the age group. The decision, however, lies with the regulator, reports Sohini......
Drug firm Zydus Cadila on Thursday said it has launched Remdesivir under the brand name Remdac, used to treat patients suffering from severe symptoms of COVID-19, in the Indian market. ......
The Drugs Controller General of India has approved emergency use for Zydus Cadila's Pegylated Interferon alpha-2b, 'Virafin' for treating moderate COVID-19 infection in adults. A release by Cadila......
Cadila Healthcare Ltd has informed BSE that pursuant to Order dated January 31, 2003 passed by Hon'ble High Court of Gujarat in the matter of approval of Scheme of Amalgamation of German Remedies......
Cadila Healthcare Ltd board approved amalgamation of German Remedies Ltd, Recon Healthcare Ltd, Zydus Pathline Ltd & Zoom Properties Ltd with the company.The boards of Cadila Health Care and German......
Cadila Healthcare Ltd has posted a net profit of Rs 172.91 million for the quarter ended December 31, 2002 as compared to Rs 147.03 million for the quarter ended December 31, 2001. Total income has......
A meeting of the board of Cadila Healthcare Ltd will be held on January 29 to consider the quarterly results for the third quarter ended December 31, 2002.BSE Code:...
The Board of Directors of German Remedies Ltd at their meeting held on January 15, 2003 decided in principle under Section 391/394 and other applicable provisions of the Companies Act 1956 for the......